American Portfolios Advisors’s AbCellera Biologics ABCL Stock Holding History

American Portfolios Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$742	Hold	75	–	–	﹤0.01%	3327
2022 Q2	$799	Hold	75	–	–	﹤0.01%	3319
2022 Q1	$731	Sell	75 -200	-73%	-$1.89K	﹤0.01%	3420
2021 Q4	$3.93K	Hold	275	–	–	﹤0.01%	2985
2021 Q3	$5.51K	Sell	275 -100	-27%	-$1.77K	﹤0.01%	2812
2021 Q2	$8.25K	Buy	375 +300	+400%	+$8.27K	﹤0.01%	2608
2021 Q1	$2.55K	Buy	+75	New	+$2.99K	﹤0.01%	2929

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

GCAC

Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

American Portfolios Advisors's ABCL Position: Q3 2022 in Review

American Portfolios Advisors held its AbCellera Biologics (ABCL) position steady in Q3 2022 at 75 shares worth $742. The position accounts for ﹤0.01% of the portfolio, ranked #3327.

American Portfolios Advisors first reported a position in ABCL in Q1 2021 and has held it in 7 quarters since. The position peaked at $8.25K in Q2 2021. 190 funds tracked by Wall St. Rank hold ABCL as of Q3 2022.

American Portfolios Advisors held 75 shares of AbCellera Biologics worth $742 as of Q3 2022.
American Portfolios Advisors left its AbCellera Biologics share count unchanged in Q3 2022.
AbCellera Biologics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #3327 holding.
American Portfolios Advisors first reported a position in AbCellera Biologics in Q1 2021 and has held it in 7 quarters since.
American Portfolios Advisors's AbCellera Biologics position peaked at $8.25K in Q2 2021.
190 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.